Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis

.The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib is approved by the Food and Drug Administration for its use as first-line treatment in chronic lymphocytic leukemia (CLL). Despite its efficacy, patients treated with ibrutinib rarely achieve complete responses and usually remain under treatmen...

Descripción completa

Detalles Bibliográficos
Autores: Colado, Ana, Genoula, Melanie, Cougoule, Céline, Marin Franco, Jose Luis, Almejún, María Belén, Risnik, Denise Mariel, Kviatcovsky, Denise, Podaza, Enrique Arturo, Elías, Esteban Enrique, Fuentes, Federico, Maridonneau Parini, Isabelle, Bezares, Fernando R., Fernandez Grecco, Horacio, Cabrejo, María del Rosario, Jancic, Carolina Cristina, Sasiain, María del Carmen, Giordano, Mirta Nilda, Gamberale, Romina, Balboa, Luciana, Borge, Mercedes
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2018
País:Argentina
Institución:Consejo Nacional de Investigaciones Científicas y Técnicas
Repositorio:CONICET Digital (CONICET)
Idioma:inglés
OAI Identifier:oai:ri.conicet.gov.ar:11336/95956
Acceso en línea:http://hdl.handle.net/11336/95956
Access Level:acceso abierto
Palabra clave:CLL
ibrutinib
mycobacteria
https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
Descripción
Sumario:.The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib is approved by the Food and Drug Administration for its use as first-line treatment in chronic lymphocytic leukemia (CLL). Despite its efficacy, patients treated with ibrutinib rarely achieve complete responses and usually remain under treatment until progression.

Similares en LA Referencia